Physician profile
Lawrence Grill
NPI 1063443844
$898.82
in general payments reported to CMS, 2019-2025
14 companies · $791 in 2025
The $791 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.14 · 2024: $91.76 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $339.36 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $122.24 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $113.81 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $65.76 | 2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $42.93 | 2025 | |
| Pfizer INC. | $38.33 | 2025 | |
| Phathom Pharmaceuticals, INC. | $38.13 | 2025 | Voquezna |
| Globus Medical, INC. | $29.25 | 2025 | Senza |
| Novo Nordisk INC | $29.03 | 2025 | |
| Sumitomo Pharma America, INC. | $17.52 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2025 | Jardiance |
| Amgen INC. | $16.91 | 2025 | Repatha |
| Shield Therapeutics INC | $14.80 | 2025 | |
| Currax Pharmaceuticals LLC | $13.75 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Grill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.